ProCE Banner Activity

QUAZAR AML-001: Phase III Study of CC-486 Maintenance Therapy in Patients With Acute Myeloid Leukemia in First Remission

Slideset Download
Conference Coverage
Significant improvement in OS and RFS with CC-486 (oral azacitidine) maintenance therapy in patients with AML in first remission with intensive induction chemotherapy.

Released: December 15, 2019

Expiration: December 13, 2020

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Celgene

Dova Pharmaceuticals

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Karyopharm Therapeutics

Loxo Oncology subsidiary of Eli Lilly

Pharmacyclics an AbbVie Company